Home › NDC Lookup › Ingredients › Albumin Human › 44206-0251-10
AlbuRx ALBUMIN (HUMAN) 12.5 g/50mL Solution — NDC 44206-0251-10 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

AlbuRx ALBUMIN (HUMAN) 12.5 g/50mL Solution — NDC 44206-251-10 (Billing 44206-0251-10)

by CSL Behring AG · 1 VIAL, GLASS in 1 CARTON / 100 mL in 1 VIAL, GLASS

This is a package of AlbuRx ALBUMIN (HUMAN) 12.5 g/50mL Solution from CSL Behring AG, marketed since Jan 2009 and currently FDA-listed. It is the main listing for this product, which comes in 2 package sizes.

NDC 44206-0251-10
🏷️ FDA NDC (as labeled) 44206-251-10 billing pads the product segment with a zero
This package
Contains100 mL in 1 vial, glass Medicaid pays$0.7991 / unit · 12 mo Per package$79.91 / 100 ml · Medicaid Pack sizes2 compare ↓
Main listing for product 44206-251 · Also comes in: 50 mL 44206-251-05
Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 44206-251-10 alone.

Record
FDA NDC Directory package listing · Plasma derivative
Code segments
44206 labeler · 251 product · 10 package
Package marketed since
Jan 6, 2009
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 4420625110 2
Medicaid fills, this package
3,418 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 44206-251-10
Product NDC 44206-251
11-digit billing NDC 44206025110
NCPDP billing unit ML — per mL (volume)
Application # BLA102366
SPL Set ID ad74b7f5-b380-47ab-b19d-eef92c8eb7a4
Established class (EPC) Human Serum Albumin
Mechanism of action Osmotic Activity
Physiologic effect Increased Intravascular Volume; Increased Oncotic Pressure
Chemical class Serum Albumin
DEA schedule Non-controlled
Marketing category BLA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2009-01-06
Route INTRAVENOUS
Dosage form SOLUTION
Substance ALBUMIN HUMAN
Biologic (Purple Book) 351(a)

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 85400010002015
GPI class Albumin Human
GCN Seq No 006331
GCN 25060
HICL code 002728
Ingredient (HICL) Albumin Human
HIC1 code M
Therapeutic class — broad (HIC1) Blood
HIC2 code M0
Therapeutic class — intermediate (HIC2) Blood And Blood Replacement Preparations
HIC3 code M0B
Therapeutic class — specific (HIC3) Plasma Proteins
AHFS code 16:00.00.00
AHFS class Blood Derivatives
FDB label name ALBURX (HUMAN) 25% VIAL
FDB brand name Alburx
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 006331
  • GCN: 25060
  • GPI-14 (Medi-Span): 85400010002015
  • HICL (First Databank): 002728
  • AHFS class code: 16:00.00.00
Why two NDCs? The FDA registers this code as 44206-251-10 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 44206-0251-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name ALBURX (HUMAN) 25% VIAL Ingredient Albumin Human

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo $0.7991 $79.91 / 100 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
44206-0251-05 44206-251-05 1 VIAL, GLASS in 1 CARTON / 50 mL in 1 VIAL, GLASS 2009-01-06 — Active
44206-0251-10 You're viewing this Main listing 1 VIAL, GLASS in 1 CARTON / 100 mL in 1 VIAL, GLASS 2009-01-06 — Active

In Medicaid, this is the most-dispensed pack of this product — about 68% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 vial, glass in 1 carton / 100 ml in 1 vial, glass.
What NDC number is used to bill for this package of AlbuRx ALBUMIN (HUMAN) 12.5 g/50mL Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
AlbuRx 12.5 g/50mLthis 44206-0251-10 CSL 1 vial — — FDA listed —
Kedbumin 12.5 g/50mL 76179-0025-02 Kedrion 1 vial — — FDA listed —
Albutein 12.5 g/50mL 68516-5216-00 GRIFOLS 100 ml — — FDA listed —
About this product: this is a biologic. Biologics don't have small-molecule generics — competition comes from FDA-licensed biosimilars (shown above), not generics.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & biosimilar status

🏛️
1976
First FDA approval
Jul 1976
📍
2026
Currently FDA-listed
50 years listed
🧬
·
Biosimilars
see Purple Book
🧬Biologic — competition comes from biosimilars

Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.

FDA Purple Book — biosimilars & interchangeables ⓘ
Reference product
Albuked, Plasbumin-20, Plasbumin-25, Plasbumin-5Albumin (Human) Albumin (Human) Albuminar, Albuminar-20, Albuminar-25, Albuminar-5Albumin (Human) AlbuminexAlbumin (Human)-kjda AlburxAlbumin (Human) AlbuteinAlbumin (Human) Buminate, FlexbuminAlbumin (Human) Human Albumin GrifolsAlbumin (Human) KedbuminAlbumin (Human)
🔒 No FDA-licensed biosimilars or interchangeable biosimilars are listed yet for this biologic. It currently has no biosimilar competition in the FDA Purple Book.
Source: FDA Purple Book (purplebooksearch.fda.gov), matched on the reference product’s active ingredient.
Where does this data come from?
Patents and exclusivity from the FDA Purple Book (biologics), refreshed from public FDA data. Biosimilar launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 3EN9H0M2FX
    A salt form of an amino acid derivative used as a solubilizer and stabilizer in liquid and injectable formulations. It helps keep active ingredients dissolved and protected from degradation during storage.
  • UNII 660YQ98I10
    Potassium chloride is a mineral salt used in medicines as a buffer and to help maintain the proper pH balance and stability of the formulation during storage and use.
  • UNII 9XTM81VK2B
    Sodium caprylate is a salt derived from caprylic acid, a naturally occurring fatty acid. In medicines, it acts as a preservative and antimicrobial agent to help prevent contamination and extend shelf life.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerCSL Behring AG
FDA applicationBLA102366 (BLA)
Labeler code44206
First marketedJan 2009
Product typePlasma Derivative
Portfolio14 products on file

More NDCs from CSL Behring AG labeler code 44206

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description ⚠️ Precautions 📚 References 📄 Package Label / Principal Display Panel
🎯 Indications and Usage ~3 min read ▾

3. INDICATIONS AND USAGE

3.1General Principles 17 3.1.1 Volume Deficit Since the oncotic pressure of AlbuRx ® 25, Albumin (Human) 25% solution is about four times higher than that of normal human serum, it will expand the plasma volume if interstitial water is available for an inflow through the capillary walls. However, many patients suffering from an acute volume deficit also have some degree of interstitial dehydration. In the absence of hyperhydration, the treatment of an acute volume deficit with AlbuRx ® 25 should therefore include isotonic electrolyte solutions with an albumin:electrolyte ratio of 1:3 or 1:4.

By contrast, chronic volume deficits have usually been at least partially compensated for by the renal retention of sodium and water with some degree of tissue edema, and in these circumstances a trial with AlbuRx ® 25 only is indicated. In any case, an anemia of clinically relevant magnitude requires specific treatment, and the metabolic needs of the patient with respect to fluid and electrolytes must be cared for. 3.1.2 Oncotic Deficit The common causes of hypoproteinemia are protein-calorie malnutrition, defective absorption in gastro-intestinal disorders, faulty albumin synthesis in chronic hepatic failure, increased protein catabolism postoperatively or with sepsis, and abnormal renal losses of albumin with chronic kidney disease.

In all these settings, the circulating albumin mass is initially maintained by a gradual transfer of extravascular albumin to the circulation, and hypoproteinemia ensues only when this compensatory potential has been exhausted. This implies that manifest hypoproteinemia is usually accompanied by a hidden extravascular albumin deficit of equal magnitude as the measurable intravascular deficit, which must be allowed for if AlbuRx ® 25, Albumin (Human) 25% solution is infused because of the capillary permeability of that protein.

The primary sequel of the oncotic deficit resulting from hypoproteinemia is a loss of plasma and a gain of interstitial volume with increased lymphatic flow. As a secondary response, the kidney retains sodium and water which distribute themselves on both sides of the capillary walls and the plasma volume may be returned almost to normal when the interstitial hydrostatic pressure increases sufficiently to compensate for the decrease of the serum oncotic pressure. This chain of events is accelerated by the infusion of crystalloid fluids.

The plasma volume is maintained at the price of interstitial edema. 2 There is some evidence that a serum oncotic pressure near 20 mmHg – equaling a total serum protein (TSP) concentration of 5.2 g/100 mL – represents a threshold, below which the risk of complications increases. 17 The target organs of hypoproteinemia include the skin, the lungs, and the intestine.

10 Cutaneous edema lowers the oxygen tension of wounds and may thus impair the healing process. 5 An oncotic deficit favors the development of interstitial pulmonary edema 4 and the intestinal accumulation of fluids, which may progress to a paralytic ileus. 9 Relief of the basic pathology is the definitive mode of therapy for the restoration of the plasma protein content, but this process takes time to become effective, and the rapid correction of a critical oncotic deficit by the administration of AlbuRx ® 25, Albumin (Human) 25% solution – possibly in conjunction with a diuretic – may therefore be indicated, particularly in high-risk patients who have undergone abdominal, cardio-vascular, thoracic, or urologic surgery or who have acute bacteremia.

In notably catabolic patients, attempts to raise the TSP level above 6 g/100 mL usually prove futile, even with massive doses of Albumin (Human). 17 It is emphasized that whereas AlbuRx ® 25, Albumin (Human) 25% solution may be necessary to prevent or treat the aforementioned acute complications of hypoproteinemia, it is not indicated for treatment of the chronic condition itself.

3.2Specific Indications 17 3.2.1 Acute ci… [Excerpted — this section continues on DailyMed.]

⏱️ Dosage and Administration ~2 min read ▾

8. DOSAGE AND ADMINISTRATION AlbuRx ® 25, Albumin (Human) 25% solution must be administered intravenously. The venipuncture site should not be infected or traumatized, and should be prepared with standard aseptic technique.

The solution is compatible with whole blood or packed red cells as well as the usual electrolyte and carbohydrate solutions intended for intravenous use. By contrast, it should not be mixed with protein hydrolysates, amino acid mixtures, or solutions containing alcohol. It is ready for use as contained in the bottle and may be given without regard to the blood group of the recipient.

The dosage of AlbuRx ® 25, Albumin (Human) 25% solution is based on the principles outlined in the section on indications but should always be adapted to the individual situation. The quantities required may be underestimated because of hidden extravascular deficits, and the effect of AlbuRx ® 25 infusion on the serum protein level should therefore be checked by laboratory analysis.

8.1Volume Deficit The appropriate AlbuRx ® 25, Albumin (Human) 25% solution dose for the treatment of a volume deficit should be estimated from the recipient's hemodynamic response 7 , supplemented with the established safeguards against a circulatory overload. In the absence of active hemorrhage, the total dose should at any rate not exceed the normal circulating albumin mass, i.e. 2 g per kg body weight.

8.2Oncotic Deficit The appropriate AlbuRx ® 25, Albumin (Human) 25% solution dose in grams of protein for the correction of an oncotic deficit can, as an average, be estimated from the difference between the desired and the actual TSP level x plasma volume (~40 mL/kg) × 2, the latter factor allowing for the hidden extravascular deficit. The individual effect is, however, variable and should be checked by measuring the post-infusion TSP level. 10,17

8.3Hemolytic Disease of the Newborn The appropriate AlbuRx ® 25, Albumin (Human) 25% solution dose for the binding of free serum bilirubin in severely hemolytic infants is 1 g/kg body weight, to be given about one hour prior to the exchange transfusion, and caution is recommended in hypervolemic infants. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

⛔ Contraindications 35 words ▾

4. CONTRAINDICATIONS The only specific contraindication to the use of AlbuRx ® 25, Albumin (Human) 25% solution is a history of an incompatibility reaction to Albumin (Human) in the individual recipient (see ADVERSE REACTIONS ).

⚠️ Warnings ~1 min read ▾

5. WARNINGS AlbuRx ® 25, Albumin (Human) 25% solution is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, that can cause disease.

The risk that such products will transmit an infectious agent has been extremely reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses through alcohol fractionation and through heat treatment of the product in the final container for 10 hours at 60°C. Despite these measures, such products can still potentially transmit disease. A theoretical risk for transmission of Creutzfeldt-Jakob Disease (CJD) is considered extremely remote.

No cases of transmission of viral diseases or CJD have ever been identified for Albumin (Human). There is also the possibility that unknown infectious agents may be present in such products. All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to CSL Behring at 1-800-504-5434.

The physician should discuss the risks and benefits of this product with the patient. Turbid solutions must not be used. Do not begin administration more than 4 hours after introduction of the administration set.

Partially used bottles must be discarded. There exists a risk of potentially fatal hemolysis and acute renal failure from the inappropriate use of sterile water for injection as a diluent for AlbuRx ® 25, Albumin (Human) 25% solution. Acceptable diluents include 0.9% sodium chloride or 5% dextrose in water.

🤒 Adverse Reactions 86 words ▾

7. ADVERSE REACTIONS Since AlbuRx ® 25, Albumin (Human) 25% solution is sterile when coming from the manufacturer, bacterial contamination with the risk of post-infusion septicemia can only occur if the container has been damaged or following puncture of the rubber cap (see WARNINGS ). Though very rare, non-septic incompatibility reactions including nausea, chills, fever, urticaria, headache and hypotension following the administration of albumin-containing preparations have been recorded.

8,11,12,17 A favorable response was observed to the intravenous administration of 50 to 100 mg of prednisolone. 12

🤰 Pregnancy 93 words ▾

Pregnancy Category C Animal reproduction studies have not been conducted with AlbuRx ® 25, Albumin (Human) 25% solution. It is also not known whether AlbuRx ® 25 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. AlbuRx ® 25 should be given to a pregnant woman only if clearly needed.

There is, however, no evidence for any contraindication to the use of AlbuRx ® 25 specifically associated with reproduction, pregnancy or the fetus. Use an intravenous infusion set suitable for the infusion of blood and blood products.

🧬 Clinical Pharmacology ~1 min read ▾

2. CLINICAL PHARMACOLOGY 13,17

2.1AlbuRx ® 25, Albumin (Human) 25% solution should not be used as an intravenous nutrient because of the slow breakdown and relatively unfavorable composition of the albumin molecule with respect to its content of essential amino acids. Oral provision of proteins or an intravenous regimen providing adequate calories and a suitable amino acid mixture are the methods of choice for the treatment of protein malnutrition as such, though they do not permit the rapid correction of hypoproteinemia.

2.2The binding properties of albumin may provide an indication for its use in severe hemolytic disease of the newborn, where it may lower the plasma concentration of free bilirubin pending an exchange transfusion. This effect is possibly also relevant in certain cases of acute liver failure with rapidly increasing levels of serum bilirubin, particularly in the presence of severe hypoproteinemia.

2.3The colloid osmotic or oncotic properties of albumin at this moment constitute the predominant reason for its clinical use. The rationale for this is the Starling concept of the capillary balance of hydrostatic and oncotic pressure gradients across the capillary walls as the determinant of the fluid – i.e. volume – distribution between the intravascular and the interstitial compartment. 16 The two main indications for the use of AlbuRx ® 25, Albumin (Human) 25% solution are therefore a plasma or blood volume deficit and the oncotic deficit resulting from hypoproteinemia.

The 25% concentration is oncotically equivalent to approximately five times its volume of normal human plasma. The effective colloid osmotic pressure of the serum proteins depends very largely on the relatively small and numerous albumin molecules, which therefore play a decisive role in the maintenance of the circulating plasma volume.

📦 How Supplied / Storage and Handling 28 words ▾

9. HOW SUPPLIED AlbuRx ® 25, Albumin (Human) 25% solution is supplied in 50 mL (NDC 44206-251-05) and 100 mL (NDC 44206-251-10) vials, with complete directions for use.

📦 Storage and Handling 32 words ▾

10. STORAGE AlbuRx ® 25, Albumin (Human) 25% solution should be stored at a temperature not exceeding 30°C (86°F). It should not be used after the expiration date printed on the label.

📋 Description 142 words ▾

1. DESCRIPTION AlbuRx ® 25, Albumin (Human) 25% solution is a sterile aqueous solution for intravenous administration containing the albumin component of human blood. This product is prepared from the plasma of US donors.

The product has been produced by alcohol fractionation and has been heated for 10 hours at 60°C for inactivation of infectious agents. The results of virus validation studies have shown that the manufacturing process, particularly alcohol fractionation, eliminates enveloped and non-enveloped viruses. Additionally, heat treatment at 60°C for a period of 10 hours efficiently inactivates viruses.

The solution contains 130-160 milliequivalents of sodium per liter (mEq/L) and the potassium content is not over 2 mEq/L. The aluminum content does not exceed 200 µg/L. The solution is stabilized with 0.08 millimole of sodium acetyltryptophanate plus 0.08 millimole of sodium caprylate per gram of albumin.

The solution contains no preservative.

⚠️ Precautions 138 words ▾

6. PRECAUTIONS Adequate precautions should be taken against circulatory overload and may include pulmonary auscultation or X-ray as well as monitoring the central venous or pulmonary artery wedge pressure. Special caution is indicated in patients with stabilized chronic anemia, congestive heart failure and renal insufficiency.

Pregnancy Category C Animal reproduction studies have not been conducted with AlbuRx ® 25, Albumin (Human) 25% solution. It is also not known whether AlbuRx ® 25 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. AlbuRx ® 25 should be given to a pregnant woman only if clearly needed.

There is, however, no evidence for any contraindication to the use of AlbuRx ® 25 specifically associated with reproduction, pregnancy or the fetus. Use an intravenous infusion set suitable for the infusion of blood and blood products.

📚 References ~1 min read ▾

REFERENCES Birke G, Liljedahl SO, Plantin LO, Reizenstein P. Acta Chir. Scand .

1968;134:27. Cervera AL, Moss G. J.

Trauma . 1974;14:506. Clowes GH Jr, Vucinic M, Weidner MG.

Ann. Surg . 1966;163:866.

Gaar KA Jr, Taylor AE, Owens LJ, Guyton AC. Amer. J.

Physiol . 1967;213:79. Heughan C, Niinikoski J, Hunt TK.

Surg. Gynec. Obstet .

1972;135:257. Hoye RC, Paulson DF, Ketcham AS. Surg.

Gynec. Obstet . 1970;131:943.

Kinney JM, Egdahl RH, Zuidema GD. Manual of Preoperative and Postoperative Care, American College of Surgeons . Philadelphia: W.

B. Saunders Co; 1971. Lowenstein E.

In: Sgouris JT, René A, ed. Proceedings of the Workshop on Albumin, February 12–13 . Bethesda, Maryland 20014: DHEW Publication NIH 76-925, NHLI; , p.

302, 1975. Moss G. Surg.

Forum . 1967;18:333. Pappova E, Bachmeier W, Crevoisier JL, Kollar J, Kollar M, Tobler P, Zahler HW, Zaugg D, Lundsgaard-Hansen P.

Vox Sang . 1977;33:307. Ring J, Messmer K.

Lancet . 1977;1:466. Ring J, Seifert J, Lob G, Coulin K, Brendel W.

Klin. Wschr . 1974;52:595.

Sgouris JT, René A, ed. Proceedings of the Workshop on Albumin, February 12–13 . Bethesda, Maryland 20014: DHEW Publication NIH 76-925, NHLI; 1975.

Skillman JJ, Parikh BM, Tanenbaum BJ. Amer. J.

Surg . 1970;119:440. Skillman JJ, Tanenbaum BJ.

Current Topics in Surgical Research . New York: Academic Press; 1970;2:523. Starling EH.

J. Physiol . 1896;19:312-326.

Tullis JL. JAMA . 1977;237:355,460.

📄 Package Label / Principal Display Panel 60 words ▾

Package Label - Principal Display Panel - 50 mL NDC 44206-251-05 25% AlbuRx ® 25 Albumin (Human) 25% Solution 50 mL For intravenous administration Rx only CSL Behring Front Package

Package Label - Principal Display Panel - 100 mL NDC 44206-251-10 25% AlbuRx ® 25 Albumin (Human) 25% Solution 100 mL For intravenous administration Rx only CSL Behring Front Package

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
3.4K
Units reimbursed last 4 qtrs
719.3K
Gross reimbursed last 4 qtrs
$574.8K
Avg / prescription
$168.17
Avg / unit
$0.7991
Latest quarter Q1 2026
740Rx
Fee-for-service vs managed care ⓘ
24% FFS 76% MCO
Fee-for-service · 837 Rx Managed care · 2,581 Rx
State Medicaid map
Alaska: 2,500 units · 341 per 100k residents AK Maine: no data reported ME Washington: no data reported WA Idaho: 8,470 units · 431 per 100k residents ID Montana: 3,200 units · 283 per 100k residents MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 1,600 units · 15.9 per 100k residents MI New York: no data reported NY Vermont: no data reported VT New Hampshire: 2,600 units · 185 per 100k residents NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 3,600 units · 112 per 100k residents IA Illinois: 73,700 units · 587 per 100k residents IL Indiana: 32,450 units · 473 per 100k residents IN Ohio: 21,600 units · 183 per 100k residents OH Pennsylvania: 26,450 units · 204 per 100k residents PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: 64,650 units · 166 per 100k residents CA Utah: 160,000 units · 4,682 per 100k residents UT Colorado: no data reported CO Nebraska: 17,050 units · 862 per 100k residents NE Missouri: 29,600 units · 478 per 100k residents MO Kentucky: 37,407 units · 826 per 100k residents KY West Virginia: no data reported WV Virginia: 81,550 units · 936 per 100k residents VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: 25,150 units · 1,190 per 100k residents NM Kansas: 1,550 units · 52.7 per 100k residents KS Arkansas: no data reported AR Tennessee: 25,612 units · 359 per 100k residents TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: 36,850 units · 909 per 100k residents OK Louisiana: 6,650 units · 145 per 100k residents LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: 11,300 units · 102 per 100k residents GA D.C.: no data reported DC Hawaii: 6,401 units · 446 per 100k residents HI Texas: no data reported TX Florida: 39,400 units · 174 per 100k residents FL
Units reimbursed · per 100k residents
15.94,682
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Utah 4,682 /100k
2 New Mexico 1,190 /100k
3 Virginia 936 /100k
4 Oklahoma 909 /100k
5 Nebraska 862 /100k
6 Kentucky 826 /100k
7 Illinois 587 /100k
8 Missouri 478 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 vial this page44206-0251-10 3,418 Rx · $574,789
1 vial44206-0251-05 1,617 Rx · $277,055
Drug total (last 4 qtrs): 5,035 Rx · 1,017,410 units · $851,844 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2025 (Q1-Q4)

Medicare Part D (outpatient prescription) spending for Alburx — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Alburx. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Total Part D spend
$9.2K
Claims incl. refills
20
Beneficiaries
13
Spend / beneficiary
$705.78
Spend / claim
$458.76
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for ALBUMIN (HUMAN) — the ingredient across all brands.

Top reported reactions

Renal Failure391
Pyrexia328
Pain319
Dyspnoea278
Pneumonia273
Injury270
Hypotension264

Age at onset

Neonate37
Infant16
Child36
Adolescent29
Adult486
Elderly417

Reporter sex

4,768 reports
Male · 55%
Female · 45%
Unknown · 0%

Serious outcomes

Hospitalization2,418
Life-threatening941
Disabling143
Reports over time (by year) — tap or hover for the count & year
2022 2023 2024 2026 603 252
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by CSL Behring AG. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 1 vial (44206-0251-05). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
CSL Behring AG is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 44183-0850-09 · Currax 44206-0300-01 · CSL →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.